AR056024A1 - Derivados de acido 3- oxo-indazol-escuarico - Google Patents

Derivados de acido 3- oxo-indazol-escuarico

Info

Publication number
AR056024A1
AR056024A1 ARP060103477A ARP060103477A AR056024A1 AR 056024 A1 AR056024 A1 AR 056024A1 AR P060103477 A ARP060103477 A AR P060103477A AR P060103477 A ARP060103477 A AR P060103477A AR 056024 A1 AR056024 A1 AR 056024A1
Authority
AR
Argentina
Prior art keywords
hal
so2nh2
nhso2a
cooa
conh2
Prior art date
Application number
ARP060103477A
Other languages
English (en)
Inventor
Guenter Hoelzemann
Helene Crassier
Wilfried Rautenberg
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR056024A1 publication Critical patent/AR056024A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de ácido escuárico de la formula (1), en donde: R1 es H, A, Hal, CN, NO2, C(=O)A, CHO, CH(OH)A, NH2, NH(C=O)A, COOH, COOA, SO2NH2, CONH2, CONA2, (CH2)mAr o Het; R2 es OH, OA, Hal, CF3, SO2NH2, NHAc o NHSO2A; R2', R2'' son en cada caso, de modo independiente entre sí, H o Hal; Ac es acetilo; Ar es fenilo no sustituido o mono-, di- o trisustituido con Hal, A, OH, OA, NH2, NO2, CN, COOH, COOA, CONH2, NHCOA, NHCONH2, NHSO2A, SO2NH2 y/o S(O)mA; Het es furilo, tienilo, pirrolilo, imidazolilo, piridilo, pirimidinilo, pirazolilo, tiazolilo o indolilo no sustituido o mono-, di- o trisustituido con A, Hal, OH y/u OA; A es alquilo no ramificado o ramificado C1-10, en donde 1-7 átomos de H pueden estar reemplazados por F; X está ausente, es CH2, CHA, CA2 o una formula (2); m es 0, 1 o 2; n es 1, 2, 3 o 4; así como sus derivados, tautomeros, sales, solvatos y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las quinasas CHK1, CHK2 y SGK y se pueden utilizar, por ejemplo, para el tratamiento de enfermedades y dolencias tales como cáncer, diabetes, obesidad, síndrome metabolico (dislipidemia), hipertonía sistémica y pulmonar, enfermedades cardiocirculatorias y nefropatías, en general con cualquier tipo de fibrosis y procesos inflamatorios.
ARP060103477A 2005-08-09 2006-08-09 Derivados de acido 3- oxo-indazol-escuarico AR056024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005037499A DE102005037499A1 (de) 2005-08-09 2005-08-09 Pyrazolderivate

Publications (1)

Publication Number Publication Date
AR056024A1 true AR056024A1 (es) 2007-09-12

Family

ID=37004918

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103477A AR056024A1 (es) 2005-08-09 2006-08-09 Derivados de acido 3- oxo-indazol-escuarico

Country Status (9)

Country Link
US (1) US7662827B2 (es)
EP (1) EP1912998B1 (es)
JP (1) JP2009504582A (es)
AR (1) AR056024A1 (es)
AU (1) AU2006278862B2 (es)
CA (1) CA2618524C (es)
DE (1) DE102005037499A1 (es)
ES (1) ES2406737T3 (es)
WO (1) WO2007017083A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623221T3 (es) 2005-05-20 2017-07-10 Methylgene Inc Inhibidores de la señalización del receptor de VEGF y del receptor de HGF
WO2007053343A2 (en) * 2005-10-28 2007-05-10 Irm Llc Compounds and compositions as protein kinase inhibitors
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
EP2276346B1 (en) * 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
CN102333770B (zh) 2008-12-11 2015-01-28 瑞斯比维特有限公司 P38map激酶抑制剂
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8334315B2 (en) 2009-05-07 2012-12-18 Gruenenthal Gmbh Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
CA2998647A1 (en) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
CN106432240B (zh) * 2016-09-21 2018-11-09 四川大学 含腺嘌呤结构的芳香族二胺及其制备方法和含腺嘌呤结构的聚酰亚胺及其制备方法
EP3774797A1 (en) 2018-04-05 2021-02-17 Merck Patent GmbH Heteroaryl compounds as type ii irak inhibitors and uses hereof
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE MENIN-MLL INTERACTION INHIBITORS
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ATE300299T1 (de) * 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
ES2155817T3 (es) 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
PL341356A1 (en) 1997-12-22 2001-04-09 Bayer Ag Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
EP1041982B1 (en) * 1997-12-22 2011-10-19 Bayer HealthCare LLC INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
KR100709497B1 (ko) * 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
DE60228103D1 (de) 2001-10-02 2008-09-18 Smithkline Beecham Corp Chemische verbindungen
WO2003032989A1 (en) * 2001-10-18 2003-04-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
CA2516624C (en) * 2003-02-28 2013-05-14 Bayer Pharmaceuticals Corporation 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders
US20070010529A1 (en) * 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
EA012613B1 (ru) * 2004-12-06 2009-10-30 Авентис Фарма С.А. Замещённые индолы, содержащие их композиции, способ получения и применение
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20080207647A1 (en) 2008-08-28
JP2009504582A (ja) 2009-02-05
AU2006278862B2 (en) 2011-11-17
AU2006278862A1 (en) 2007-02-15
EP1912998A1 (de) 2008-04-23
CA2618524C (en) 2014-05-13
CA2618524A1 (en) 2007-02-15
ES2406737T3 (es) 2013-06-07
EP1912998B1 (de) 2013-03-06
US7662827B2 (en) 2010-02-16
WO2007017083A1 (de) 2007-02-15
DE102005037499A1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
AR056024A1 (es) Derivados de acido 3- oxo-indazol-escuarico
AR056636A1 (es) Derivados del acido escuarico
AR061913A1 (es) Derivados de aminoindazolurea, procesos de obtencion y composiciones farmaceuticas.
AR059908A1 (es) Derivados de 4-(pirrolopiridinil)-pirimidinil-2-amina
AR053838A1 (es) Derivados de acido indazol-escuarico 2
AR055126A1 (es) Derivados de acido 3-oxo-indazol-escuarico
AR056877A1 (es) Sulfonamidas biciclicas como moduladores de receptor glucocorticoide utiles para enfermedades inflamatorias
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
CY1117078T1 (el) Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων
AR059955A1 (es) Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
AR077567A1 (es) Derivados de aminopiridina
AR067506A1 (es) Derivados de quinazolinamida
AR061735A1 (es) Derivados de indazol, composiciones farmaceuticas y uso de los mismos
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
RS51674B (en) PIPERIDIN-4-IL-PIRIDAZIN-3-ILAMINE DERIVATIVES AS A FAST DISSOCATING DOPAMIN 2 RECEIVER ANTAGONISTS
AR046061A1 (es) Derivados de acilhidrazona
DK2229358T3 (da) Indoler og deres terapeutiske anvendelse
AR066557A1 (es) Derivados de 1h-indazol-5-il-[1, 3, 4]oxadiazol-2-ilo, un metodo para su preparacion, y el uso de los mismos en medicamentos para el tratamiento de enfermedades mediadas por la modulacion de la sgk.
AR053569A1 (es) Derivados de pirazol
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
CR10034A (es) Derivados de oxadiazol
BRPI0417337A (pt) agentes anti-enxaqueca heterocìclicos
AR056958A1 (es) Acilhidrazidas
UY30465A1 (es) Azolilmetiloxiranos, sus uso para combatir hongos fitopatógenos, así como productos que los contienen (v)
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина

Legal Events

Date Code Title Description
FB Suspension of granting procedure